Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic StrokeCompleted
NCT05953480Phase 2Updated Jul 30, 2026
Sponsor: Shionogi
Acute Ischemic Stroke
United States, Australia, Belgium, China, Czechia +12 more
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruiting
NCT06380751Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
United States, Argentina, Australia, Austria, Brazil +24 more
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigraineActive Not Recruiting
NCT06616194Phase 3Updated Jul 30, 2026
Sponsor: Pfizer
Migraine
United States, Canada, China, Czechia, Finland +7 more
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompleted
NCT06323356Phase 3Updated Jul 30, 2026
Sponsor: Takeda
Generalized Pustular Psoriasis · Erythrodermic Psoriasis
Japan
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Recruiting
NCT06585787Phase 3Updated Jul 30, 2026
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Alzheimer Disease
United States, Argentina, Belgium, Brazil, Bulgaria +20 more
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active Not Recruiting
NCT06710132Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Solid Tumors · Gastric Cancer · Non-Small Cell Lung Cancer (NSCLC) · Pancreatic Cancer
United States, Australia, Austria, China, France +5 more
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary LesionsRecruiting
NCT06959524NAUpdated Jul 30, 2026
Sponsor: Boston Scientific Corporation
Coronary Arterial Disease (CAD) · de Novo Lesions in Native Coronary Arteries
United States, Australia, China, Germany, Ireland +4 more
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 MonthsWithdrawn
NCT06904274Phase 3Updated Jul 30, 2026
Sponsor: Bayer
Endometrial Hyperplasia
United States, Canada, China
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)Recruiting
NCT07293351Phase 1, Phase 2Updated Jul 30, 2026
Sponsor: Bristol-Myers Squibb
Advanced Renal Cell Carcinoma (RCC)
United States, Argentina, Australia, Brazil, Canada +16 more
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Active Not Recruiting
NCT06122779Phase 2Updated Jul 30, 2026
Sponsor: Bristol-Myers Squibb
Heart Failure
United States, Argentina, Canada, China, Israel +6 more
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseCompleted
NCT04673357Phase 3Updated Jul 30, 2026
Sponsor: Janssen Research & Development, LLC
Crohn Disease
United States, Belgium, Germany, Hungary, Israel +4 more
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsRecruiting
NCT03435796Phase 2, Phase 3Updated Jul 30, 2026
Sponsor: Celgene
Neoplasms
United States, Australia, Austria, Belgium, Canada +15 more
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation SystemCompleted
NCT02439775NAUpdated Jul 30, 2026
Sponsor: Medtronic Vascular
Hypertension · Vascular Diseases · Cardiovascular Diseases
United States, Australia, Austria, Canada, France +5 more
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain TumoursRecruiting
NCT07441707Phase 1Updated Jul 30, 2026
Sponsor: Ipsen
Low-grade Glioma
Japan
Study of Ravulizumab in Pediatric Participants With Primary IgANRecruiting
NCT07024563Phase 3Updated Jul 30, 2026
Sponsor: Alexion Pharmaceuticals, Inc.
IgAN · IgAVN · Immunoglobulin A Nephropathy · Immunoglobulin A Vasculitis Associated Nephritis
United States, China, Italy, Japan, South Korea +2 more
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia AreataActive Not Recruiting
NCT07023302Phase 3Updated Jul 30, 2026
Sponsor: AbbVie
Alopecia Areata
Japan
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active Not Recruiting
NCT05464030Phase 1Updated Jul 30, 2026
Sponsor: EMD Serono Research & Development Institute, Inc.
Colorectal Cancer
United States, Canada, Japan, South Korea, Spain
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.Recruiting
NCT07543120Phase 2Updated Jul 30, 2026
Sponsor: Novartis Pharmaceuticals
Hypertension (HTN)
United States, Japan, Singapore
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisRecruiting
NCT06598943Phase 2Updated Jul 30, 2026
Sponsor: Eli Lilly and Company
Ulcerative Colitis · Ulcerative Colitis Chronic
United States, Argentina, Belgium, Canada, Colombia +16 more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)Recruiting
NCT06170788Phase 3Updated Jul 30, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Argentina, Australia, Brazil, Canada +21 more
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive Not Recruiting
NCT06208150Phase 3Updated Jul 30, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Argentina, Australia, Austria, Belgium +22 more
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive Not Recruiting
NCT02938520Phase 3Updated Jul 30, 2026
Sponsor: ViiV Healthcare
HIV Infections
United States, Canada, France, Germany, Italy +6 more
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerCompleted
NCT02632409Phase 3Updated Jul 30, 2026
Sponsor: Bristol-Myers Squibb
Various Advanced Cancer
United States, Argentina, Australia, Austria, Belgium +25 more
A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaEnrolling By Invitation
NCT07204938Phase 3Updated Jul 30, 2026
Sponsor: Astria Therapeutics, Inc.
Hereditary Angioedema (HAE)
United States, Brazil, Bulgaria, Canada, Czechia +13 more
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionCompleted
NCT06034743Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Uncontrolled Hypertension · Resistant Hypertension
United States, Argentina, Australia, Austria, Belgium +24 more

Previous page Next page